Valeant Pharmaceuticals International (VRX) : 15 analysts are covering Valeant Pharmaceuticals International (VRX) and their average rating on the stock is 2.87, which is read as a Hold. 4 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 5, which recommends a Strong Sell affirms that they expect a large upside in the stock from the current levels. However, 3 analysts consider that the stock has more downward risks ahead, hence, they suggest a Strong Sell on the stock. A total of 8 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.
Valeant Pharmaceuticals International (VRX) : Currently there are 12 street experts covering Valeant Pharmaceuticals International (VRX) stock. The most bullish and bearish price target for the stock is $90 and $11 respectively for the short term. The average price target of all the analysts comes to $39.75. The estimated standard deviation from the target is $19.53.
Company shares have received an average consensus rating of Hold for the current week Also, BMO Capital initiates coverage on Valeant Pharmaceuticals International (NYSE:VRX). The rating major has initiated the coverage with market perform rating on the shares. The rating by the firm was issued on June 29, 2016.
Valeant Pharmaceuticals International (NYSE:VRX): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $21.07 and $20.93 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $22.56. The buying momentum continued till the end and the stock did not give up its gains. It closed at $22.36, notching a gain of 5.62% for the day. The total traded volume was 14,906,993 . The stock had closed at $21.17 on the previous day.
Valeant Pharmaceuticals International, Inc. is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries. The Company operates through two segments: developed markets and emerging markets. The Companys developed markets segment consists of sales in the United States of pharmaceutical products, OTC products, and medical device products. The Companys Emerging Markets segment consists of branded generic pharmaceutical products and branded pharmaceuticals, OTC products, and medical device products.